Ekso Bionics Raises $5.3M via Convertible Preferred Stock Offering
Summary
Ekso Bionics finalized a $5.3 million private placement, issuing convertible preferred stock and warrants to institutional investors. The proceeds will be used for working capital and general corporate purposes.
Key Events
-
Private Placement Completed
Ekso Bionics closed a private placement, issuing Series B Convertible Preferred Stock and warrants, raising approximately $5.3 million after fees.
-
Proceeds Allocated
The company intends to use the net proceeds for working capital and general corporate purposes.
-
Registration Rights Agreement
Ekso Bionics has agreed to file a registration statement for the resale of conversion shares and warrant shares by June 1, 2026.
Analysis
Ekso Bionics secured $5.3 million through a private placement, issuing Series B Convertible Preferred Stock and warrants. This capital infusion will support working capital and general corporate needs. The offering includes warrants and preferred stock redeemable after one year, suggesting a need for capital but also offering potential returns to investors.
At the time of this filing, EKSO was trading at $7.90 on NASDAQ in the Technology sector, with a market capitalization of approximately $26.8M. The 52-week trading range was $2.73 to $12.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.